The aforementioned research shed light on microbiota dysbiosis (or gut microbiota-derived metabolites)-mediated NLRP3 inflammasome activation in atherosclerosis, supporting the possibility of development of treatment options including gut microbiota composition manipulation in combating atherosclerosis. This evidence concerns the gene NLRP3 and atherosclerosis.